This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Hi-Yo Silver!

Click here for an archive of Cramer's "Mad Money" recaps.


Drug Paraphernalia

Want a new drug? Jim Cramer had two for his "Mad Money" TV show viewers on Monday.

He said that ACP-103 and ACP-104, which are being developed by Acadia Pharmaceuticals (ACAD - Get Report), could make you some mad money.

The company makes antipsychotic drugs, said Cramer, and he believes that Acadia could change the way we treat schizophrenia and bipolar disorder.

Interim results from phase II trials for ACP-103 are coming out soon as a treatment for Parkinson's, he said, adding that more results are due out later in the year.

Plus, Cramer said that ACP-104 has phase II results coming out later this year for its antipsychotic that he said is basically a better version of the widely used antipsychotic Clozapine.

Clozapine has some very bad side effects, he said; and it's off patent, so no one can make any money from it.

If all of these tests fail, Cramer said the stock could go down three points or so from its current level above $10. But if it nails the trials, he believes the stock could run to $50.

Sepracor (SEPR), the maker of Lunesta, has already invested in Acadia, and Cramer believes more investment could come soon.

A caller wanted to know about American Shared Hospital Services (AMS - Get Report), which is also working on a Parkinson's treatment.

Cramer said the company is interesting and profitable, but it has a market cap of only $31 million. He likes to look at companies with a minimum market cap of $200 million to $250 million.

That's because if he praised a company as small as American Shared Hospital Services on the show, he fears that there would not be enough supply to meet demand, and people would get hurt.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMS $2.50 0.00%
ACAD $41.69 0.00%
GG $16.18 0.00%
PAAS $8.49 0.00%
AAPL $126.44 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs